15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection: a cross-sectional study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The Absolute cardiovascular disease (CVD) risk evaluation using multivariable CVD risk models is increasingly advocated in people with HIV, in whom existing models remain largely untested. We assessed the agreement between the general population derived Framingham CVD risk equation and the HIV-specific Data collection on Adverse effects of anti-HIV Drugs (DAD) CVD risk equation in HIV-infected adult Cameroonians.

          Methods

          This cross-sectional study involved 452 HIV infected adults recruited at the HIV day-care unit of the Yaoundé Central Hospital, Cameroon. The 5-year projected CVD risk was estimated for each participant using the DAD and Framingham CVD risk equations. Agreement between estimates from these equations was assessed using the spearman correlation and Cohen’s kappa coefficient.

          Results

          The mean age of participants (80% females) was 44.4 ± 9.8 years. Most participants (88.5%) were on antiretroviral treatment with 93.3% of them receiving first-line regimen. The most frequent cardiovascular risk factors were abdominal obesity (43.1%) and dyslipidemia (33.8%). The median estimated 5-year CVD risk was 0.6% (25th-75th percentiles: 0.3-1.3) using the DAD equation and 0.7% (0.2-2.0) with the Framingham equation. The Spearman correlation between the two estimates was 0.93 ( p < 0.001). The kappa statistic was 0.61 (95% confident interval: 0.54-0.67) for the agreement between the two equations in classifying participants across risk categories defined as low, moderate, high and very high.

          Conclusion

          Most participants had a low-to-moderate estimated CVD risk, with acceptable level of agreement between the general and HIV-specific equations in ranking CVD risk.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Cardiovascular disease risk profiles.

          This article presents prediction equations for several cardiovascular disease endpoints, which are based on measurements of several known risk factors. Subjects (n = 5573) were original and offspring subjects in the Framingham Heart Study, aged 30 to 74 years, and initially free of cardiovascular disease. Equations to predict risk for the following were developed: myocardial infarction, coronary heart disease (CHD), death from CHD, stroke, cardiovascular disease, and death from cardiovascular disease. The equations demonstrated the potential importance of controlling multiple risk factors (blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking, glucose intolerance, and left ventricular hypertrophy) as opposed to focusing on one single risk factor. The parametric model used was seen to have several advantages over existing standard regression models. Unlike logistic regression, it can provide predictions for different lengths of time, and probabilities can be expressed in a more straightforward way than the Cox proportional hazards model.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

            HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda.

              To report the prevalence of hypertension and projected 10-year absolute risk of acute cardiovascular disease in a large prospectively followed cohort of HIV-positive youth and adults beginning antiretroviral therapy in sub-Saharan Africa. HIV-positive individuals seeking HIV treatment, ages 13 years and older, were assessed for repeated blood pressure measurements over the first year following initiation of antiretroviral therapy, including serum total cholesterol, high-density lipoprotein, CD4 cell count and related clinical and laboratory measurements. Outcomes include hypertension, defined according to the 7th Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure categories, and Framingham Risk Score based 10-year cardiovascular disease risk estimates. Five thousand, five hundred and sixty-three patients had at least two blood pressure measurements on at least two separate occasions during the first year of antiretroviral therapy [median age of therapy initiation 34, first and third quartile (Q1-Q3) 28-40 years, 1841 (33.1%) men, baseline CD4 cell count 161 cells/μl (Q1-Q3 72-231 cells/μl]. Hypertension was diagnosed in 1551 patients [27.9%, 95% confidence interval (CI) 26.7- 29.1] including 786 (14.1%, 95% CI 13.2-15.1) who met criteria for stage 2 hypertension. The age-standardized prevalence for Ugandans aged 13 or more was 24.8% (95% CI 23.8-26.1). Among those with complete laboratory studies (n=1102), nearly all women were in the 10% or less 10-year Framingham Risk Score category, but 20% of men were at at least 10% or more long-term risk of acute cardiovascular disease. Efforts to combine HIV treatment with vascular disease risk factor prevention and management are urgently needed to address noncommunicable disease multimorbidity in HIV-positive persons in sub-Saharan Africa, particularly in men.
                Bookmark

                Author and article information

                Contributors
                stevenoumegni91@yahoo.com
                movicky@yahoo.fr
                kembeassah@yahoo.com
                bignarimjj@yahoo.fr
                jobertrichie_nansseu@yahoo.fr
                kamsarielle@yahoo.com
                jckatte@gmail.com
                ydehayem@yahoo.com
                apkengne@yahoo.com
                sobngwieugene@yahoo.fr
                Journal
                Trop Dis Travel Med Vaccines
                Trop Dis Travel Med Vaccines
                Tropical Diseases, Travel Medicine and Vaccines
                BioMed Central (London )
                2055-0936
                5 July 2017
                5 July 2017
                2017
                : 3
                : 12
                Affiliations
                [1 ]ISNI 0000 0001 2173 8504, GRID grid.412661.6, Faculty of Medicine and Biomedical Sciences, , University of Yaoundé 1, ; PO Box 1364, Yaoundé, Cameroon
                [2 ]Faculty of Medicine, University of Paris Sud XI, 63 Av Gabriel Péri, Le Kremlin Bicêtre, France
                [3 ]ISNI 0000 0001 2173 8504, GRID grid.412661.6, Department of Biochemistry and Physiological Sciences, Faculty of Medicine and Biomedical Sciences, , University of Yaoundé 1, ; PO Box 1364, Yaoundé, Cameroon
                [4 ]Laboratory of Biochemistry, University Teaching Hospital, Yaoundé, Cameroon
                [5 ]ISNI 0000 0001 2173 8504, GRID grid.412661.6, Department of Public Health, Faculty of Medicine and Biomedical Sciences, , University of Yaoundé 1, ; PO Box 1364, Yaoundé, Cameroon
                [6 ]Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, PO Box 1274, Yaoundé, Cameroon
                [7 ]ISNI 0000 0001 2184 581X, GRID grid.8364.9, , University of Mons, ; 20 place du parc PO, 7000 Mons, Belgium
                [8 ]National Obesity Center, Yaoundé Central Hospital, PO Box 87, Yaoundé, Cameroon
                [9 ]ISNI 0000 0000 9155 0024, GRID grid.415021.3, , Non-Communicable Diseases Research Unit, South African Medical Research Council, ; Cape Town, 7505 South Africa
                [10 ]Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, 8000 South Africa
                [11 ]ISNI 0000 0001 2173 8504, GRID grid.412661.6, Departement of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, , University of Yaoundé 1, ; PO Box 1364, Yaoundé, Cameroon
                [12 ]ISNI 0000 0001 2173 8504, GRID grid.412661.6, Laboratory of Molecular Medicine and Metabolism, Biotechnology Center, , University of Yaoundé 1, ; Yaoundé, Cameroon
                Article
                55
                10.1186/s40794-017-0055-z
                5531007
                aaeff664-981a-4909-b42f-a07f8f07bd40
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 16 February 2017
                : 7 June 2017
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                cardiovascular risk,hiv,framingham,dad
                cardiovascular risk, hiv, framingham, dad

                Comments

                Comment on this article